Subtler scopes: Where IRA drug negotiations meet Part D redesigns
Understanding how the IRA’s multiple provisions interact to induce cost-related change The...
Topic
Government
Navigating the impacts of the Inflation Reduction Act (IRA): Strategic considerations for pharma
With a few years now into the enactment of the Inflation Reduction Act (IRA), the law continues...
TrOOPs: Tracking cost implications under IRA Part D reforms
As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic...
Why RWE programs fail under regulatory scrutiny — and what leaders can do about it
FDA has made its expectations for RWE clearer and more structured through recent guidance and...
How the FDA is using real-world evidence in safety and approval decisions
Regulatory decision-making depends on evidence that reflects how medical products perform in...
Trusted by the NSF: How HealthVerity set the standard for secure data linkage
When two federal agencies, the National Center for Science and Engineering Statistics (NCSES) and...
How government agencies use HealthVerity for public health and AI-powered research
Government health agencies are increasingly turning to real-world data (RWD) for public health...
HealthVerity real-world data supports CDC study on HIV PrEP surveillance
A new peer-reviewed study from the Centers for Disease Control and Prevention (CDC) highlights the...
What is Privacy Preserving Record Linkage (PPRL)?
Author: Emery Niemiec, Director, Partners & Alliance at HealthVerity Privacy preserving record...